Genmab A/S (GMAB) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$34.91

From 52W high−1.70%

Volume2.71M

Market cap$21.36B

P/E (TTM)27.2x

P/S (TTM)5.2x

Div yield—

Key dataSep 18, 2026

Open

$34.91

From 52W high

−1.70%

Volume

2.71M

Market cap

$21.36B

ValuationView details →

P/E (Fwd)

26.4x

EV/EBITDA

20.6x

P/E (TTM)

27.2x

RSI (14)

65.5

MomentumView details →

1D Return

+0.59%

YTD Return

+13.28%

SummaryUpdated Jun 1, 2026

Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. The company went public in 2009 and has established itself as a leading developer of innovative antibody therapeutics for cancer treatment. Genmab has evolved from a research-focused biotech startup into a commercially successful company with multiple approved products and a robust pipeline of experimental treatments. The company operates through strategic partnerships with major pharmaceutical companies while also developing and commercializing its own proprietary medicines.

Ask drillr about Genmab A/S →

ValuationView details →

P/E (Fwd)

26.4x

P/E (TTM)

27.2x

EV/EBITDA

20.6x

EV/Sales

6.1x

P/S (TTM)

5.2x

P/B (TTM)

3.6x

ProfitabilityView details →

Gross Margin

93.03%

Net Margin

19.08%

EBITDA Margin

29.52%

ROE (TTM)

13.23%

ROA (TTM)

6.30%

Asset Turnover

0.33x

GrowthView details →

Revenue YoY

−68.25%

EPS YoY

−85.02%

FCF YoY

−66.56%

Revenue CAGR 3Y

−36.45%

EPS CAGR 3Y

−42.93%

EBITDA YoY

−75.83%

MomentumView details →

1D Return

+0.59%

YTD Return

+13.28%

1Y Return

+23.37%

RSI (14)

65.5

vs 50D SMA

+11.07%

vs 200D SMA

+18.45%

Capital & dividendView details →

Debt/Equity

0.89x

Current Ratio

2.46x

Quick Ratio

2.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.54

EPS Surprise

45.95%

Beats (12Q)

6/12

Next Q EPS Est

$0.38

Avg Surprise (4Q)

−1.94%

Rev Surprise

3.46%

Financials snapshotView financials →

Revenue (TTM)

4.13B

Net Income (TTM)

788.10M

Op. CF (TTM)

890.35M

Next earningsNov 5, 2026 →

Latest newsMore news →

Genmab A/S increased its share capital by 28,011 shares due to the exercise of employee warrants, without preemption rights for existing shareholders.12d ago

Genmab announced two new Phase III studies of petosemtamab in colorectal cancer.45d ago

Similar companies

United Therapeutics CorporationUTHR Keymed Biosciences Inc.02162.HK Metis Techbio-p07666.HK Zai Lab Limited09688.HK 大参林603233.SH 天坛生物600161.SH Find similar companies →

Latest newsMore news →

Genmab A/S increased its share capital by 28,011 shares due to the exercise of employee warrants, without preemption rights for existing shareholders.12d ago Genmab announced two new Phase III studies of petosemtamab in colorectal cancer.45d ago